| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$344,220 ) |
| | 2025 | 2021 | LIGNAMED, LLC | 490 BELFRY DR | BLUE BELL | PA | 19422-1202 | MONTGOMERY | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 000 | 4 | NIH | 8/19/2025 | -$75,207 |
| | 2025 | 2021 | LIGNAMED, LLC | 490 BELFRY DR | BLUE BELL | PA | 19422-1202 | MONTGOMERY | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 001 | 4 | NIH | 8/29/2025 | -$77,025 |
| | 2025 | 2021 | LIGNAMED, LLC | 490 BELFRY DR | BLUE BELL | PA | 19422-1202 | MONTGOMERY | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 3 | NIH | 12/29/2024 | -$191,989 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | LIGNAMED, LLC | 3675 MARKET ST STE 200 | PHILADELPHIA | PA | 19104-2897 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 3 | NIH | 10/20/2023 | $0 |
| | 2024 | 2021 | LIGNAMED, LLC | 490 BELFRY DR | BLUE BELL | PA | 19422-1202 | MONTGOMERY | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 001 | 3 | NIH | 4/19/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$75,207 ) |
| | 2023 | 2021 | LIGNAMED, LLC | 3675 MARKET ST STE 200 | PHILADELPHIA | PA | 19104-2897 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 3 | NIH | 3/10/2023 | $0 |
| | 2023 | 2021 | LIGNAMED, LLC | 490 BELFRY DR | BLUE BELL | PA | 19422-1202 | MONTGOMERY | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 000 | 4 | NIH | 9/19/2023 | -$75,207 |
|
| Issue Date FY: 2021 ( Subtotal = $1,880,443 ) |
| | 2021 | 2021 | LIGNAMED, LLC | 3675 MARKET ST STE 200 | PHILADELPHIA | PA | 19104-2897 | PHILADELPHIA | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 000 | 4 | NIH | 6/9/2021 | $964,295 |
| | 2021 | 2021 | LIGNAMED, LLC | 3675 MARKET ST STE 200 | PHILADELPHIA | PA | 19104-2897 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 3 | NIH | 2/15/2021 | $916,148 |
| | 2021 | 2021 | LIGNAMED, LLC | 3675 MARKET ST STE 200 | PHILADELPHIA | PA | 19104-2897 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 001 | 3 | NIH | 7/13/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,440,044 ) |
| | 2020 | 2020 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 001 | 2 | NIH | 2/10/2020 | $1,440,044 |
| | 2020 | 2020 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 000 | 3 | NIH | 6/29/2020 | $1,000,000 |
| | 2020 | 2018 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R41HL142384 | Graft-protective properties of LGM2605 in Lung Transplantation | 000 | 1 | NIH | 1/31/2020 | $0 |
| | 2020 | 2018 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 002 | 1 | NIH | 9/16/2020 | $0 |
| | 2020 | 2018 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 1 | NIH | 2/6/2020 | $0 |
| | 2020 | 2017 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R41AI132012 | Effects of LGM2605 on a Primate Model of Asthma | 000 | 1 | NIH | 8/25/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,000,000 ) |
| | 2019 | 2019 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R42AI132012 | IND enabling development of LGM2605 as adjuvant treatment for asthma | 000 | 2 | NIH | 7/25/2019 | $1,000,000 |
| | 2019 | 2017 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R41AI132012 | Effects of LGM2605 on a Primate Model of Asthma | 000 | 1 | NIH | 1/4/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $599,286 ) |
| | 2018 | 2018 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R41HL142384 | Graft-protective properties of LGM2605 in Lung Transplantation | 000 | 1 | NIH | 7/26/2018 | $299,599 |
| | 2018 | 2018 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R44HL140680 | Optimization of LGM2605 for use as a device in lung transplant | 000 | 1 | NIH | 8/15/2018 | $299,687 |
|
| Issue Date FY: 2017 ( Subtotal = $277,792 ) |
| | 2017 | 2017 | LIGNAMED, LLC | 3711 MARKET ST STE 866 | PHILADELPHIA | PA | 19104-5504 | PHILADELPHIA | USA | R41AI132012 | Effects of LGM2605 on a Primate Model of Asthma | 000 | 1 | NIH | 7/17/2017 | $277,792 |
|
|
